Emerging Trends to Reshape the Cell and Gene Therapy Market: Car T-Cell Therapy's Impact On The Cell And Gene Therapy Market as a Key Influencer

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

Cell and Gene Therapy Market Size Growth Forecast: What to Expect by 2025?
The size of the cell and gene therapy market has seen a substantial expansion in the past few years. It's expected to increase from the previous $12.01 billion value in 2024 to a projected $15.48 billion in 2025, representing a compound annual growth rate (CAGR) of 28.9%. This growth during the historic period is mainly a result of increased investment in cell and gene therapies, enhanced research and development, progress in the discovery of cancer drugs, the emergence of public-private partnerships, robust economic growth in developing markets, escalated healthcare expenses, and an increase in pharmaceutical R&D expenditure.

How Will the Cell and Gene Therapy Market Size Evolve and Grow by 2029?
The market for cell and gene therapy is anticipated to experience a substantial increase in the coming years, expanding to $29.15 billion in 2029 with a compound annual growth rate (CAGR) of 17.1%. This projected growth can be linked to factors such as the rising instances of cancer and long-term illnesses, an increasing elderly population, enhanced emphasis on cell and gene therapy, and an increase in healthcare spending. Key trends for the forecast period encompass emphasizing advanced therapies like chimeric antigen receptor (CAR) T-cell therapy, focusing on pursuing varied research prospects and securing funding, executing strategic partnerships to amalgamate advanced technologies, focusing on the creation of gene or genome editing tools, particularly CRISPR, engaging in partnerships or acquisitions with rival firms, escalating the number of pipeline studies to formulate cell and gene therapies, and pumping in investments for the augmentation of manufacturing facilities.

View the full report here:
https://www.thebusinessresearchcompany.com/report/cell-and-genes-therapy-global-market-report

What Drivers Are Propelling the Growth of Cell and Gene Therapy Market Forward?
The growth of the cell and gene therapy (CGT) market has been fuelled by consistent investment and consolidation in cell and gene therapies. Sixteen of the top 20 biopharmaceutical companies by revenue have recognized the potential of this market and included CGT products in their range. For example, in 2023, the BioIndustry Association (BIA), a UK-based entity that represents the life sciences and biotech sectors, noted that UK cell and gene therapy firms secured over 55% of the venture capital funding won by European companies. The UK usually accounts for about a third of all European venture capital investments in the life sciences, underscoring the strength of its CGT sector. The growth of the market is also tied to the consistent investment and consolidation in CGT manufacturing capacity, which has resulted in escalated production. For instance, Purespring Therapeutics, a biotech company in the UK, received an investment of $105 million in October 2024. This funding was meant to aid the progression of gene therapies for kidney diseases, including a phase 1/2 trial for the study of a new treatment for immunoglobulin A nephropathy (IgAN). Purespring uses adeno-associated viruses (AAVs) to convey its gene therapies into the body.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3472&type=smp

Which Emerging Trends Are Transforming the Cell and Gene Therapy Market in 2025?
The Chimeric antigen receptor (CAR) T-cell therapy is actively transforming the cell and gene therapy (CGT) sector. It entails the genetically engineering of T cells obtained from the patient's blood to generate modified cellular receptors, which are identified as chimeric antigen receptors (CARs). Once these engineered T cells with unique receptors are reintroduced into the patient, they aid in identifying and targeting the cancer cell's surface antigen, resulting in the eradication of tumor cells. To exemplify, Bristol-Myers Squibb Company, an American pharmaceutical corporation, got approval in June 2022 for their CAR T cell therapy Breyanzi, designed for adults with large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma. Breyanzi is a unique CAR T cell therapy formulated from the patient's own T cells that are gathered, genetically altered to become CAR T cells and then dispensed as a single-time treatment through infusion.

What Are the Key Segments in the Cell and Gene Therapy Market?
The cell and gene therapy market covered in this report is segmented -

1) By Product: Cell Therapy, Gene Therapy
2) By Application: Oncology, Neurological Disorders, Other Applications
3) By End User: Hospitals, Ambulatory Surgical Centers, Cancer Care Centers, Wound Care Centers, Other End-Users

Subsegments:
1) By Cell Therapy: Autologous Cell Therapy, Allogeneic Cell Therapy, Stem Cell Therapy, CAR-T Cell Therapy
2) By Gene Therapy: Viral Vector-Based Gene Therapy, Non-Viral Vector-Based Gene Therapy, Genome Editing Technologies, Antisense Oligonucleotide Therapy

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=3472&type=smp

Who Are the Key Players Shaping the Cell and Gene Therapy Market's Competitive Landscape?
Major companies operating in the cell and gene therapy market include Biogen Inc., Novartis AG, Gilead Sciences, Ionis Pharmaceuticals Inc., Alnylam Pharmaceuticals Inc., ArrowHead Pharmaceuticals Inc., Spark Therapeutics, Bluebird Bio Inc., RegenexBio, Mesoblast Limited, Biocon, Cipla, Stempeutics Research Pvt. Ltd., EdiGene Inc., Immunochina, Takara Bio, Daiichi Sankyo Company, Ultragenyx Pharmaceutical Inc, Mitsubishi Tanabe Pharma, Oxford Biomedica plc, Santen Pharmaceutical Co., Therapeutic Innovation Australia, Merck, GenScript, Cellular Biomedicine Group, GE Healthcare, inStem, Lonza, Nikon CeLL innovation Co. Ltd., Bristol-Myers Squibb, Amgen, Pfizer, Kite Pharma, Oxford BioTherapeutics, Freeline Therapeutics, PsiOxus Therapeutics, Herantis Pharma Plc, AstraZeneca

What Geographic Markets Are Powering Growth in the Cell and Gene Therapy Market?
North America was the largest region in the cell and gene therapy market in 2024. The regions covered in the cell and gene therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=3472

This Report Supports:
1. Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2. Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3. Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4. Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.